Form 4: Definitive Healthcare CLO Granted 481,505 RSUs

Definitive Healthcare's Chief Legal Officer, Jonathan Paris, was granted 481,505 restricted stock units, vesting over four years.

Summary

• Jonathan Paris, Chief Legal Officer of Definitive Healthcare Corp. (DH), was granted 481,505 restricted stock units (RSUs).
• Each RSU represents a contingent right to receive one share of the Issuer's Class A Common Stock.
• The transaction date for this acquisition was February 24, 2026.
• The RSUs will vest 25% on March 1, 2027, followed by 6.25% every three months thereafter over the subsequent three years.
• Vesting is subject to Mr. Paris's continued service with the Issuer through each vesting date.
• Following this transaction, Jonathan Paris beneficially owns 902,854 shares of Class A Common Stock.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it strengthens the alignment of executive interests with long-term shareholder value, a standard and healthy corporate governance practice.

Positives

• The RSU grant aligns the Chief Legal Officer's long-term interests with those of shareholders, incentivizing sustained company performance.
• The vesting schedule encourages executive retention over a multi-year period.

Negatives

• The future issuance of shares upon RSU vesting will result in a minor dilutive effect on existing shareholders, though spread over several years.

Future Outlook

The RSU grant establishes a long-term incentive structure for the Chief Legal Officer, with vesting scheduled through March 2030, contingent on continued service.

Industry Context

StockSavvy.ai notes that granting restricted stock units is a standard and widely adopted practice in executive compensation across various industries, particularly in technology and healthcare sectors, to attract, retain, and motivate key personnel by linking their compensation directly to the company's long-term stock performance.

Comparison to Industry Standards

• The use of RSUs with a multi-year vesting schedule is a common compensation mechanism, comparable to practices at companies like Veeva Systems (VEEV) or IQVIA Holdings (IQV), which frequently utilize similar equity grants to align executive incentives with shareholder value.
• The grant size for a Chief Legal Officer is within typical ranges for a company of Definitive Healthcare's market capitalization, reflecting competitive executive compensation packages in the healthcare technology space.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for increased long-term value creation due to aligned executive incentives; minor future dilution upon vesting.
• Employees: Reinforces the company's commitment to performance-based compensation for key leadership.
• Management: Provides a significant long-term equity incentive tied to continued service and company performance.

Next Steps

• The RSUs will begin vesting on March 1, 2027, with subsequent vesting occurring quarterly over the following three years.

Key Dates

Keywords

Definitive Healthcare, DH, Jonathan Paris, Restricted Stock Units, RSU Grant, Executive Compensation, Insider Transaction, Form 4, Equity Compensation